(1) Background: The coronavirus (COVID-19) pandemic is still a major global health problem, despite the development of several vaccines and diagnostic assays. Moreover, the broad symptoms, from none to severe pneumonia, and the various responses to vaccines and the assays, make infection control challenging. Therefore, there is an urgent need to develop non-invasive biomarkers to quickly determine the infection severity. Circulating RNAs have been proven to be potential biomarkers for a variety of diseases, including infectious ones. This study aimed to develop a genetic network related to cytokines, with clinical validation for early infection severity prediction. (2) Methods: Extensive analyses of in silico data have established a novel IL11RA molecular network (IL11RNA mRNA, LncRNAs RP11-773H22.4 and hsa-miR-4257). We used different databases to confirm its validity. The differential expression within the retrieved network was clinically validated using quantitative RT-PCR, along with routine assessment diagnostic markers (CRP, LDH, D-dimmer, procalcitonin, Ferritin), in100 infected subjects (mild and severe cases) and 100 healthy volunteers. (3) Results: IL11RNA mRNA and LncRNA RP11-773H22.4, and the IL11RA protein, were significantly upregulated, and there was concomitant downregulation of hsa-miR-4257, in infected patients, compared to the healthy controls, in concordance with the infection severity. (4) Conclusion: The in-silico data and clinical validation led to the identification of a potential RNA/protein signature network for novel predictive biomarkers, which is in agreement with ferritin and procalcitonin for determination of COVID-19 severity.
CRISPR-Cas proteins from bacteria are powerful tools for gene editing and molecular diagnostics. Expanding capacity of CRISPR to low cost, multiplexed assays of biomarkers is a key to future disease diagnostics, since multiple biomarker detection is essential for reliable diagnostics. Herein we describe a multiplexed assay in a 3D-printed 96-well plate with CRISPR-Cas13a immobilized in each well to target three circulating blood biomarker microRNAs (miRNAs 34c-5p, 200c-3p, and 30e-5p) for Alzheimer’s disease (ALZ). Immobilized Cas13a is equipped with different crRNAs complementary to each miRNA target. MiRNA binding to crRNA complements activates the collateral RNase activity of Cas13a, cleaving a quenched fluorescent reporter (RNaseAlert) with fluorophore and quencher connected by an RNA oligonucleotide to enable fluorescence measurements. We achieved ultralow limits of detection (LOD) of 0.74 fg/mL for miRNA 34c-5p, 0.70 fg/mL for miRNA 30e-5p, and 7.4 fg/mL for miRNA 200c-3p, with dynamic ranges from LODs up to about 1800 pg/mL. The accuracy of the assay was validated by spike-recovery studies and good correlation of levels of patient plasma samples vs. a referee method. This new approach provides selective, sensitive multiplex miRNA biosensing, and simultaneously accommodates analysis of standards and controls.
Hepatocellular carcinoma (HCC) is a major global health problem with about 841,000 new cases and 782,000 deaths annually, due to lacking early biomarker/s, and centralized diagnosis. Transcriptomes research despite its infancy has proved excellence in its implementation in identifying a coherent specific cancer RNAs differential expression. However, results are sometimes overlapped by other cancer types which negatively affecting specificity, plus the high cost of the equipment used.
Hepatitis C Virus (HCV) is an asymptomatic chronic infection with serious clinical consequences. Timely and sensitive detection of HCV RNA is critical for infection control, treatment response follow up. While current technologies, such as PCR or isothermal amplification-based strategies, are specific, they are expensive, labor intensive, time consuming limiting their use in field and small laboratories. We introduce a novel technology for detecting nucleic acids, as exemplified by HCV RNA, in clinical specimens. This approach utilizes the crosslinked Enhanced Emission (CEE) phenomena upon mixing fluorescent amino functionalized silica-coated nitrogen-doped carbon dots (N-CDs/SiO2/NH2) with magnetic extracted unamplified HCV RNA showed a significant and immediate fluorescence enhancement. This method was integrated into a semi-automated 3D printed microfluidic chip, wherein the unamplified RNA was mixed with the N-CDs/SiO2/NH2. The assay was also employed on the conventional 96-well plate format. This assay offers high sensitivity with detection limit of 500 IU/ml and 1000 IU/ml for the chip and well plate respectively. The sample-to-result time was <20 min on the chip and is simpler than the amplification-based techniques. Analyzing 141 patient samples yielded sensitivity and specificity of 96.47 % and 98.79 % respectively. This application of N-CDs/SiO2 as nucleic acid fluorescent probes for the first time, offers a versatile, cost-effective, and universal platform for nucleic acids detection. The developed system can be employed in conventional microwell plate-based detection with minimal modifications to current laboratory setups. Additionally, it was integrated into a 3D-printed microfluidic chip enabling enhancement in specificity, sensitivity and accuracy.